MedTrace Logo

Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

NCT02292472 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2019-03-27

No results posted yet for this study

Summary

This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.

Conditions

  • Hypertrophy of Masseter Muscle

Interventions

DRUG

Botulinum Toxin Type A

Inject intramuscularly once in visit 2

DRUG

Placebos

Inject intramuscularly once in visit 2

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • Beom Joon Kim, Ph D · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-06
Primary Completion
2015-05-24
Completion
2015-08-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02292472 on ClinicalTrials.gov